Extending the time between salon appointments - Getting your hair done everyother month instead of every month; squeezing an extra week or two out ofmanicures or pedicures (or opting to do your own) adds up.Eating at restaurants where children eat free or at a discount - If possible,avoid dining out. When you do need to eat out, visit you go -- the site highlights restaurants with special deals forfamilies."Increasing the income available to apply to your mortgage will enhance yourchances of being approved for a loan modification," said Jones. "It will alsoincrease the likelihood that you will be able to stay current on your paymentsand fulfill your responsibility to the lender."CCCS of Greater Atlanta provides free counseling for homeowners and helps themexplore the options available to them. For homeowners that may qualify for aloan modification, counselors will offer tips on documents to have availableand help them understand what they can afford. In some cases, the counselorwill participate in a conference call with the homeowner and loan servicer toinitiate conversation about a loan modification.CCCS is a member of the Homeownership Preservation Foundation, a nonprofitorganization that operates a 24-hour toll-free hotline to provide counselingfor borrowers The Homeowner's Hope Hotline number is 888-995-HOPE (4673). You can also get more information online at About CCCS of Greater AtlantaCCCS of Greater Atlanta serves clients in all 50 states and has 33 offices infour states. Arena Pharmaceuticals to Present at the Piper Jaffray Fourth Annual EuropeConferenceSAN DIEGO, June 18, 2009 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc.(Nasdaq: ARNA) announced today that the company is scheduled to present at thePiper Jaffray Fourth Annual Europe Conference on June 23, 2009 at 9:30 a.m.British Summer Time (4:30 am Eastern Time, 1:30 a.m Pacific Time) at theAndaz Hotel in London Dominic P.
Behan, Ph.D., Arena's Senior Vice Presidentand Chief Scientific Officer, is scheduled to provide an overview of thecompany, including its clinical development and research programs.A live audio webcast of the presentation will be available under the investorrelations section of Arena's website at A replay of thepresentation will be available for 30 days following the event. Please connectto Arena's website several minutes prior to the start of the webcast to ensureadequate time for any software download that may be necessary.About Arena PharmaceuticalsArena is a clinical-stage biopharmaceutical company focused on discovering,developing and commercializing oral drugs in four major therapeutic areas:cardiovascular, central nervous system, inflammatory and metabolic diseases.Arena's most advanced drug candidate, lorcaserin, is being investigated in aPhase 3 clinical trial program for weight management. Arena's broad pipelineof novel compounds target G protein-coupled receptors, an important class ofvalidated drug targets, and includes compounds being evaluated independentlyand with partners, including Merck & Co., Inc., and Ortho-McNeil-JanssenPharmaceuticals, Inc. Arena Pharmaceuticals(R) and Arena(R) are registered service marks of thecompany. "APD" is an abbreviation for Arena Pharmaceuticals Development.Forward-Looking Statements Certain statements in this press release are forward-looking statements thatinvolve a number of risks and uncertainties. Such forward-looking statementsinclude statements about Arena's strategy, internal and partnered programs,and ability to develop compounds and commercialize drugs. For such statements,Arena claims the protection of the Private Securities Litigation Reform Act of1995.
Actual events or results may differ materially from Arena'sexpectations. Factors that could cause actual results to differ materiallyfrom the forward-looking statements include, but are not limited to, Arena'sability to obtain additional funds; the timing, success and cost of Arena'slorcaserin program and other of its research and development programs; resultsof clinical trials or preclinical studies may not be predictive of futureresults; clinical trials and studies may not proceed at the time or in themanner Arena expects or at all; Arena's ability to partner lorcaserin or otherof its compounds or programs; the timing and ability of Arena to receiveregulatory approval for its drug candidates; Arena's ability to obtain anddefend its patents; and the timing and receipt of payments and fees, if any,from Arena's collaborators. Additional factors that could cause actual resultsto differ materially from those stated or implied by Arena's forward-lookingstatements are disclosed in Arena's filings with the Securities and ExchangeCommission. These forward-looking statements represent Arena's judgment as ofthe time of this release. Arena disclaims any intent or obligation to updatethese forward-looking statements, other than as may be required underapplicable law.Contacts: Jack LiefPresident and Chief Executive OfficerCindy McGeeSenior Communications AssociateArena Pharmaceuticals, Inc.858.453.7200, ext. 1479SOURCEArena Pharmaceuticals, Inc.Jack Lief, President and Chief Executive Officer, or Cindy McGee, SeniorCommunications Associate, both of Arena Pharmaceuticals, Inc.,+1-858-453-7200, ext 1479. Harris Corporation Awarded Potential $27 Million Contract Supporting DISA'sMultinational Information Sharing Program WASHINGTON, June 18 /PRNewswire-FirstCall/ -- Harris Corporation (NYSE: HRS)has been awarded a potential five-year, $27 million contract to providenetwork and systems engineering, and other key support services, for theDefense Information Systems Agency's Multinational Information Sharing (MNIS)Program Management Office.Harris is the sole subcontractor to EDS, an HPcompany, on the MNIS System Engineering/Technical Assistance (SETA) contract,which was awarded under Encore II.MNIS is a consolidated approach toensuring seamless information sharing among U.S forces and their allied andcoalition partners.
The SETA contract has a one-year base period with four, one-year options. Evans, Harris IT Services, +1-703-483-8684, ,Jim Burke, Corporate Headquarters, +1-321-727-9131, , orMarc Raimondi, Harris Corporation - Washington, D.C., +1-202-729-3732,, all of Harris. Englewood Hospital Home Health and Hospice Services Selects CardiocomTelehealth TechnologyMINNEAPOLIS, June 18 /PRNewswire/ -- Englewood Hospital Home Health andHospice Services, the oldest homecare agency in Bergen County NJ, announcedthat it has entered into a business relationship with Cardiocom(R) to provideadvanced home telehealth technology to patients with chronic illness. Cardiocom, the Experts in Telehealth(SM), is a world class developer,manufacturer and clinical service provider of award-winning telehealthsolutions.Cardiocom's telehealth system provides an interactive opportunity toproactively manage patient care.Every day, many of our cardio-respiratorypatients use the Cardiocom Commander Telehealth System to communicate theirvital signs to the agency where they are monitored by an Englewood HospitalHome Health nurse.